By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix has closed on a $6 million extension to its Series A financing round, bringing the total raised in the round to $18.6 million.

Tony Eisenhut, the firm's president, told GenomeWeb Daily News today that the funds will be used to continue developing four tests: a warfarin-sensitivity test; a sexually transmitted disease panel; an HIV panel; and a CYP2C19 test for predicting response to the anti-platelet drug Plavix (clopidogrel).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.